Wellcome Trust CRCD Fellow
- Consultant Plastic and Reconstructive Surgeon
- Lecturer in Physiology
I jointly lead the Transplantation Research Immunology Group (TRIG) together with Dr Joanna Hester. TRIG is a dynamic group of graduate students, postdoctoral researchers and junior clinical academics with an interest in immune regulation. Our work spans basic science discoveries to early phase clinical trials of novel therapeutics. My research interests are focused on manipulating the immune system with a view to improving outcomes after transplantation. I am particularly interested in the effects of hypoxia and the HIF system on immune responses as well as the mechanisms of rejection and regulation of skin transplants. Together with Dr Paul Harden and Professor Peter Friend, I am currently investigating regulatory T cell (Treg) therapy in renal transplantation in the MRC DPFS-funded Phase IIb TWO Study.
I co-Chair the Transplantation Science Committee and Young Members Committee of the TTS, and I am a member of the ESOT VCA Committee. I am an Associate Editor of the journal Transplantation. I am keen to promote basic and translational research to junior clinicians. If you are interested in joining our group in the future please get in touch with me or Joanna Hester (firstname.lastname@example.org). Open positions are always advertised in the University's Gazette and online.
Issa F., (2019), Transplantation, 103, 1526 - 1527
Selective Hematopoietic Stem Cell Ablation Using CD117-Antibody-drug-conjugates Enables Safe and Effective Transplantation With Immunity Preservation
Issa F., (2019), TRANSPLANTATION, 103, 1526 - 1526
Three Types of Functional Regulatory T Cells Control T Cell Responses at the Human Maternal-fetal Interface
Issa F., (2019), TRANSPLANTATION, 103, 1526 - 1527
Systemic silencing of HIF hydroxylase PHD2 causes reversible immunoregulatory dysfunction
YAMAMOTO A. et al, (2019), Journal of Clinical Investigation
Systemic silencing of PHD2 causes reversible immune regulatory dysfunction.
Yamamoto A. et al, (2019), J Clin Invest, 130